Bristol-Myers Squibb Company (BMY) Position Increased by Howe & Rusling Inc.

Howe & Rusling Inc. increased its holdings in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 166.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 9,087 shares of the biopharmaceutical company’s stock after acquiring an additional 5,673 shares during the quarter. Howe & Rusling Inc.’s holdings in Bristol-Myers Squibb were worth $579,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of BMY. Connecticut Wealth Management LLC bought a new stake in shares of Bristol-Myers Squibb in the first quarter valued at $224,000. Birmingham Capital Management Co. Inc. AL raised its stake in shares of Bristol-Myers Squibb by 4.4% in the first quarter. Birmingham Capital Management Co. Inc. AL now owns 70,973 shares of the biopharmaceutical company’s stock valued at $3,860,000 after buying an additional 3,000 shares during the period. HGK Asset Management Inc. raised its stake in shares of Bristol-Myers Squibb by 20.8% in the first quarter. HGK Asset Management Inc. now owns 308,825 shares of the biopharmaceutical company’s stock valued at $16,794,000 after buying an additional 53,221 shares during the period. Investment Partners Ltd. OH ADV raised its stake in shares of Bristol-Myers Squibb by 1.4% in the first quarter. Investment Partners Ltd. OH ADV now owns 20,350 shares of the biopharmaceutical company’s stock valued at $1,107,000 after buying an additional 274 shares during the period. Finally, Goelzer Investment Management Inc. raised its stake in shares of Bristol-Myers Squibb by 85.4% in the first quarter. Goelzer Investment Management Inc. now owns 75,402 shares of the biopharmaceutical company’s stock valued at $4,100,000 after buying an additional 34,735 shares during the period. Institutional investors and hedge funds own 69.82% of the company’s stock.

In related news, EVP Sandra Leung sold 156,582 shares of the business’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the completion of the transaction, the executive vice president now directly owns 584,373 shares in the company, valued at $37,031,717.01. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the business’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total value of $335,172.00. Following the transaction, the executive vice president now owns 9,251 shares of the company’s stock, valued at $585,033.24. The disclosure for this sale can be found here. 0.23% of the stock is owned by insiders.

Bristol-Myers Squibb Company (BMY) opened at $62.41 on Monday. The firm has a market capitalization of $102,154.63, a price-to-earnings ratio of 21.09, a PEG ratio of 2.37 and a beta of 1.18. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $66.10. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The business had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.20 billion. During the same quarter in the previous year, the firm earned $0.77 earnings per share. Bristol-Myers Squibb’s quarterly revenue was up 6.7% compared to the same quarter last year. analysts anticipate that Bristol-Myers Squibb Company will post 2.99 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, February 1st. Investors of record on Friday, January 5th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 2.56%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date is Thursday, January 4th. Bristol-Myers Squibb’s payout ratio is presently 61.42%.

Several analysts have issued reports on the company. BMO Capital Markets set a $49.00 target price on Bristol-Myers Squibb and gave the company a “sell” rating in a research note on Monday, December 11th. Citigroup set a $72.00 target price on Bristol-Myers Squibb and gave the company a “buy” rating in a research note on Tuesday, December 5th. Zacks Investment Research lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. SunTrust Banks upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Monday, October 30th. Finally, Credit Suisse Group reiterated a “hold” rating and issued a $61.00 price target (up from $58.00) on shares of Bristol-Myers Squibb in a research report on Friday, October 27th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $64.93.

COPYRIGHT VIOLATION WARNING: This report was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://sportsperspectives.com/2017/12/18/bristol-myers-squibb-company-bmy-position-increased-by-howe-rusling-inc.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply